The bacterial endotoxin LPS is a potent stimulator of monocyte and macrophage activation and has been shown to protect differentiated macrophages from de novo infection by HIV-1. However, the mechanisms of this inhibitory activity of LPS are not fully understood. We investigated the effect of LPS on the early post-binding steps of HIV-1 replication in primary macrophages. Paradoxically, when applied together with the virus, LPS stimulated entry of HIV-1 into macrophages, as judged by the amount of internalized HIV-1 RNA and p24. This stimulatory activity did not depend on receptors used for entry and did not require new protein synthesis. However, internalized viral RNA and p24 were rapidly degraded in LPS-stimulated macrophages. Surprisingly, while degradation of HIV-1 p24 in LPS-treated cells was inhibited by bafilomycin A1, HIV-1 RNA was not protected by this agent, suggesting that viral RNA is degraded by a pH-independent mechanism. These results indicate that LPS stimulates both virus uptake and virus degradation in macrophages.
References
1.
Gartner S., Markovits P., Markovitz DM, Betts RF, Popovic M.Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA1986; 256: 2365—2371.
2.
Gartner S., Popovic M.Macrophage tropism of HIV-1. AIDS Res Hum Retroviruses1990; 6: 1017—1021.
3.
Popovic M., Mellert W., Erfle V., Gartner S.Role of mononuclear phagocytes and accessory cells in human immunodeficiency virus type I infection of the brain. Ann Neurol1988; 23: S74—S77.
4.
Ayehunie S., Garcia-Zepeda EA, Hoxie JA et al. Human immunodeficiency virus-1 entry into purified blood dendritic cells through CC and CXC chemokine coreceptors. Blood1997; 90: 1379—1386.
5.
Ho WZ, Cherukuri R., Douglas SDThe macrophage and HIV-1. Immunol Ser1994 ; 60: 569—587.
6.
Orenstein JM , Fox C., Wahl SMMacrophages as a source of HIV during opportunistic infections. Science1997; 276: 1857—-1861.
7.
Rietschel ET , Kirikae T., Schade FU et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J1994; 8: 217—225.
8.
Pomerantz RJ , Feinberg MB, Trono D., Baltimore D.Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med1990; 172: 253—261.
9.
Bagasra O., Wright SD, Seshamma T., Oakes JW, Pomerantz RJCD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide. Proc Natl Acad Sci USA1992; 89: 6285—6289.
10.
Kornbluth RS , Oh PS, Munis JR, Cleveland PH, Richman DDInterferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med1989; 169: 1137—1151.
11.
Bernstein MS , Tong-Starksen SE, Locksley RMActivation of human monocyte-derived macrophages with lipopolysaccharide decreases human immunodeficiency virus replication in vitro at the level of gene expression. J Clin Invest1991; 88: 540—545.
12.
Verani A., Scarlatti G., Comar M. et al. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells . J Exp Med1997; 185: 805—816.
13.
Zybarth G., Reiling N., Schmidtmayerova H., Sherry B., Bukrinsky M.Activation-induced resistance of human macrophages to HIV-1 infection in vitro . J Immunol1999; 162: 400—406.
14.
Franchin G. , Zybarth G., Dai W-W. et al. Lipopolysaccharide inhibits human immunodeficiency virus type 1 infection of monocyte-derived macrophages through direct and sustained downregulation of CCR5 receptors. J Immunol2000; 164: 2592—2601.
15.
Moriuchi M. , Moriuchi H., Turner W., Fauci ASExposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1. J Clin Invest1998; 102: 1540—1550.
16.
Bukrinsky MI , Nottet HS, Schmidtmayerova H. et al. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med1995; 181: 735—745.
17.
Connor RI, Sheridan KE, Ceradini D., Choe S., Landau NRChange in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med1997 ; 185: 621—628.
18.
Dragic T., Litwin V., Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5. Nature1996; 381: 667—673.
19.
Marechal V. , Clavel F., Heard JM, Schwartz O.Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol1998; 72: 2208—2212.
20.
Schmidtmayerova H., Alfano M., Nuovo G., Bukrinsky M.Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol1998; 72: 4633—4642.
21.
Mackman N.Lipopolysaccharide induction of gene expression in human monocytic cells. Immunol Res2000; 21: 247—251.
22.
Tersmette M. , Gruters RA, de Wolf F. et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol1989; 63: 2118—2125.
23.
Mathews WC, Caperna J., Toerner JG, Barber RE, Morgenstern H.Neutropenia is a risk factor for Gram-negative bacillus bacteremia in human immunodeficiency virus-infected patients: results of a nested case-control study. Am J Epidemiol1998; 148: 1175—1183.
24.
Ashley EA, Johnson MA, Lipman MCHuman immunodeficiency virus and respiratory infection. Curr Opin Pulm Med2000; 6: 240—245.
25.
Wang SW, Pawlowski J., Wathen ST, Kinney SD, Lichenstein HS, Manthey CLCytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Inflamm Res1999; 48: 533—538.
